Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mayo Clinic proceedings 2017-04, Vol.92 (4), p.578-598
Hauptverfasser:	Dingli, David, Ailawadhi, Sikander, Bergsagel, P Leif, Buadi, Francis K, Dispenzieri, Angela, Fonseca, Rafael, Gertz, Morie A, Gonsalves, Wilson I, Hayman, Susan R, Kapoor, Prashant, Kourelis, Taxiarchis, Kumar, Shaji K, Kyle, Robert A, Lacy, Martha Q, Leung, Nelson, Lin, Yi, Lust, John A, Mikhael, Joseph R, Reeder, Craig B, Roy, Vivek, Russell, Stephen J, Sher, Taimur, Stewart, A Keith, Warsame, Rahma, Zeldenrust, Stephen R, Rajkumar, S Vincent, Chanan Khan, Asher A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Combined Chemotherapy Protocols - pharmacology Care and treatment Clinical Decision-Making Diagnosis Disease Management Evaluation Fees & charges Hematology Humans Long Term Adverse Effects - diagnosis Long Term Adverse Effects - therapy Lymphoma Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Physicians Practice guidelines (Medicine) Practice Guidelines as Topic Proteasomes Recurrence Research funding Risk Adjustment - methods Stem cells Transplants & implants Trends
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!